This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Astra Zeneca UK Ltd.
Reference
Eccleston A, et al. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value in Health : 3 Mar 2017. Available from: URL: http://dx.doi.org/10.1016/j.jval.2017.01.004
Rights and permissions
About this article
Cite this article
BRCA testing in women with ovarian cancer worth its cost. PharmacoEcon Outcomes News 774, 9 (2017). https://doi.org/10.1007/s40274-017-3833-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3833-y